Econ in the News: Morality and Medicines
In mid-August, 32-year-old Martin Shkreli, the CEO of Turing Pharmaceuticals, bought Daraprim, a small little drug that was being sold in the market for $13.50 a dose. After the acquisition, Turing increased the price more than 5000% to $750, leading to large public backlash. It’s tempting to say “moral issues aside” and just attempt to discern the … More Econ in the News: Morality and Medicines









